Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis.

Dutta D, Kamrul-Hasan ABM, Nagendra L, Bhattacharya S

TouchREVIEWS in endocrinology6 Jun 2024Cited by 12 (Europe PMC)

PMID39526060PMCIDPMC11548363DOI10.17925/ee.2024.20.2.10PepBankPUB-39526060

Summary

Aims: To date, no meta-analysis has analyzed the efficacy and safety of tirzepatide as an anti-obesity medication in individuals without diabetes. This meta-analysis was undertaken to address this knowledge gap. Materials and methods: Electronic databases were searched for randomized controlled trials (RCTs) involving individuals with obesity without diabetes receiving tirzepatide in the intervention arm and placebo in the control arm. The primary outcome was the percentage change in weight from baseline, and the secondary outcomes included the change in weight from baseline; a weight reduction of ≥5%, ≥10%, ≥15%, ≥20% and ≥25%; glycaemic parameters; lipid parameters and adverse events. Results: From 281 initially screened articles, data from 2 RCTs involving 1,852 participants were analyzed. The efficacy and safety of tirzepatide 15 mg (or the highest tolerable dose) versus placebo were analyzed. The percentage change in body weight was higher with tirzepatide than with placebo (mean difference [MD]: -19.44%; 95% confidence interval [CI]: -22.48 to -16.41; p<0.00001). Tirzepatide also had a higher absolute reduction in body weight (MD: -17.55 kg; 95% CI: -32.15 to -2.95; p<0.00001). Higher percentages of people on tirzepatide had a weight reduction of ≥5%, ≥10%, ≥15%, ≥20% and ≥25% compared with placebo. Improvements in glycaemic and cardiometabolic parameters were observed with tirzepatide. Tirzepatide was associated with a higher number of participants with one or more adverse events, which leads to treatment discontinuation, and severe or serious gastrointestinal events. Conclusion: This meta-analysis provides exciting data on the impressive weight loss properties of tirzepatide over 72 weeks of clinical use in individuals with obesity without diabetes.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled RCTs showed a greater percentage body weight reduction with tirzepatide than with placebo (mean difference -19.44%).
In plain wordsIn adults with obesity without diabetes, tirzepatide led to much more percentage weight loss than placebo in pooled trials.
Peptide
Tirzepatide
Outcome
DecreasePercentage change in body weight
Study
n = 1,852
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg or highest tolerable dose · 72 weeksAs given in this study (human).
Measurements
Mean difference in percentage weight change
−19.44%
tirzepatide vs placebo
Source sentences
Summary
The percentage change in body weight was higher with tirzepatide than with placebo (mean difference [MD]: -19.44%; 95% confidence interval [CI]: -22.48 to -16.41; p<0.00001).
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for randomized controlled trials (RCTs) involving individuals with obesity without diabetes receiving tirzepatide in the intervention arm and placebo in the control arm.
Summary · context
From 281 initially screened articles, data from 2 RCTs involving 1,852 participants were analyzed.
Show in the study text Report a problemFND-3952606001
02HumanSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled RCTs showed a larger absolute body weight reduction with tirzepatide than with placebo (mean difference -17.55 kg).
In plain wordsIn adults with obesity without diabetes, tirzepatide led to a larger loss of kilograms than placebo in pooled trials.
Peptide
Tirzepatide
Outcome
DecreaseAbsolute change in body weight
Study
n = 1,852
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg or highest tolerable dose · 72 weeksAs given in this study (human).
Measurements
Mean difference in body weight
−17.55 kg
tirzepatide vs placebo
Source sentences
Summary
Tirzepatide also had a higher absolute reduction in body weight (MD: -17.55 kg; 95% CI: -32.15 to -2.95; p<0.00001).
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for randomized controlled trials (RCTs) involving individuals with obesity without diabetes receiving tirzepatide in the intervention arm and placebo in the control arm.
Summary · context
From 281 initially screened articles, data from 2 RCTs involving 1,852 participants were analyzed.
Show in the study text Report a problemFND-3952606002
03HumanSystematic reviewEfficacy outcome
In adults with obesity without diabetes, higher percentages of people on tirzepatide than placebo had weight reductions of 5%, 10%, 15%, 20% and 25% or more.
In plain wordsIn adults with obesity without diabetes, more people lost at least 5% to 25% of their weight on tirzepatide than on placebo.
Peptide
Tirzepatide
Outcome
IncreaseProportion with weight reduction of 5%, 10%, 15%, 20% and 25% or more
Study
n = 1,852
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg or highest tolerable dose · 72 weeksAs given in this study (human).
Source sentences
Summary
Higher percentages of people on tirzepatide had a weight reduction of ≥5%, ≥10%, ≥15%, ≥20% and ≥25% compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for randomized controlled trials (RCTs) involving individuals with obesity without diabetes receiving tirzepatide in the intervention arm and placebo in the control arm.
Summary · context
From 281 initially screened articles, data from 2 RCTs involving 1,852 participants were analyzed.
Show in the study text Report a problemFND-3952606003
04HumanSystematic reviewEfficacy outcome
In adults with obesity without diabetes, the meta-analysis reported improvements in glycaemic parameters with tirzepatide versus placebo.
In plain wordsIn adults with obesity without diabetes, blood sugar measures improved with tirzepatide compared with placebo in pooled trials.
Peptide
Tirzepatide
Outcome
Direction not reportedGlycaemic parameters
Study
n = 1,852
Comparator
Placebo
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mg or highest tolerable dose · 72 weeksAs given in this study (human).
Source sentences
Summary
Improvements in glycaemic and cardiometabolic parameters were observed with tirzepatide.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for randomized controlled trials (RCTs) involving individuals with obesity without diabetes receiving tirzepatide in the intervention arm and placebo in the control arm.
Summary · context
From 281 initially screened articles, data from 2 RCTs involving 1,852 participants were analyzed.
Show in the study text Report a problemFND-3952606004
05HumanSystematic reviewEfficacy outcome
In adults with obesity without diabetes, the meta-analysis reported improvements in cardiometabolic parameters with tirzepatide versus placebo.
In plain wordsIn adults with obesity without diabetes, heart and metabolic risk measures improved with tirzepatide compared with placebo in pooled trials.
Peptide
Tirzepatide
Outcome
Direction not reportedCardiometabolic parameters
Study
n = 1,852
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
15 mg or highest tolerable dose · 72 weeksAs given in this study (human).
Source sentences
Summary
Improvements in glycaemic and cardiometabolic parameters were observed with tirzepatide.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for randomized controlled trials (RCTs) involving individuals with obesity without diabetes receiving tirzepatide in the intervention arm and placebo in the control arm.
Summary · context
From 281 initially screened articles, data from 2 RCTs involving 1,852 participants were analyzed.
Show in the study text Report a problemFND-3952606005
06HumanSystematic reviewSafety outcome
In adults with obesity without diabetes, tirzepatide was associated with more participants with adverse events leading to treatment discontinuation than placebo.
In plain wordsIn adults with obesity without diabetes, more people on tirzepatide than on placebo stopped treatment because of side effects.
Peptide
Tirzepatide
Outcome
IncreaseAdverse events leading to treatment discontinuation
Study
n = 1,852
Comparator
Placebo
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
15 mg or highest tolerable dose · 72 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide was associated with a higher number of participants with one or more adverse events, which leads to treatment discontinuation
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for randomized controlled trials (RCTs) involving individuals with obesity without diabetes receiving tirzepatide in the intervention arm and placebo in the control arm.
Summary · context
From 281 initially screened articles, data from 2 RCTs involving 1,852 participants were analyzed.
Show in the study text Report a problemFND-3952606006
07HumanSystematic reviewSafety outcome
In adults with obesity without diabetes, tirzepatide was associated with more severe or serious gastrointestinal events than placebo.
In plain wordsIn adults with obesity without diabetes, severe stomach and gut side effects were more common with tirzepatide than with placebo.
Peptide
Tirzepatide
Outcome
IncreaseSevere or serious gastrointestinal events
Study
n = 1,852
Comparator
Placebo
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
15 mg or highest tolerable dose · 72 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide was associated with a higher number of participants with one or more adverse events, which leads to treatment discontinuation, and severe or serious gastrointestinal events.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for randomized controlled trials (RCTs) involving individuals with obesity without diabetes receiving tirzepatide in the intervention arm and placebo in the control arm.
Summary · context
From 281 initially screened articles, data from 2 RCTs involving 1,852 participants were analyzed.
Show in the study text Report a problemFND-3952606007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.